404964-94-9

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(6,7-dihydroxynaphthalen-2-yl)-2-Methylpropan-1-one is used as an intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique molecular structure allows it to serve as a building block for the development of new medications.
Used in Dye and Perfume Production:
In the chemical industry, 1-(6,7-dihydroxynaphthalen-2-yl)-2-Methylpropan-1-one is used as a precursor in the production of dyes and perfumes. Its aromatic properties make it a valuable component in creating a wide range of colors and fragrances.
Used in Antioxidant-Rich Products:
Due to its strong antioxidant properties, 1-(6,7-dihydroxynaphthalen-2-yl)-2-Methylpropan-1-one is used as an additive in the development of antioxidant-rich products, particularly in the cosmetics and food industries, to enhance shelf life and provide health benefits.
Used in Chemical Reactions as a Reagent:
1-(6,7-dihydroxynaphthalen-2-yl)-2-Methylpropan-1-one is also utilized as a reagent in various chemical reactions, taking advantage of its reactive functional groups to facilitate the synthesis of other organic compounds.
Used in Research and Development:
1-(6,7-dihydroxynaphthalen-2-yl)-2-Methylpropan-1-one is used as a research tool in the scientific community to study its pharmacological effects, including its potential as an antioxidant, anti-inflammatory, and neuroprotective agent. This research could lead to the development of new therapeutic strategies for various diseases and conditions.

Upstream product

• 337522-30-2 1-(6,7-Dimethoxy-naphthalen-2-yl)-2-methyl-propan-1-one 
• 10103-06-7 2,3-dimethoxynaphthalene 
• 92-44-4 2,3-naphthalenediol 

Downstream Products

• 1610537-15-9 (S)-seviteronel 
• 1375603-36-3 1-(6,7-bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol 

Relevant academic research and scientific papers

METHODS OF TREATING CANCER USING ANDROGEN RECEPTOR ANTAGONISTS

Disclosed herein are methods of sensitizing cancer cells to an anticancer agent, methods of inhibiting the development of resistance of a cancer cell to an anticancer agent, and methods of inhibiting cancer cell proliferation, each comprising administering an androgen receptor antagonist. Also disclosed herein are methods of determining the prognosis of a subject suffering from cancer, methods of selecting a subject for therapy with an anti-cancer agent and methods of predicting a subject's response to an anti-cancer agent, each comprising determining the level of expression and/or activity of the androgen receptor and/or ZEB1 in the cytoplasm.

COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS

The instant invention describes pharmaceutical compositions and dosing regimens comprising radiation therapy and seviteronel with or without dexamethasone, and methods of treating diseases, disorders or symptoms thereof.

ANTICANCER COMPOUND PROCESS

The present invention relates to a process for preparing compound 1 that useful as an anticancer agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.

COMPOSITIONS FOR THE TREATMENT OF BREAST AND PROSTATE CANCER

The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders or symptoms thereof.

COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS

The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders symptoms thereof.

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors

The orally-active CYP17A1 inhibitor abiraterone acetate (AA) decreases adrenal and intratumoral androgen biosynthesis and is an effective agent for the treatment of prostate cancer. Abiraterone potently inhibits both reactions catalyzed by CYP17, the 17α-hydroxylase (hydroxylase) reaction as well as the 17,20-lyase (lyase) transformation. CYP17 hydroxylase inhibition prevents the synthesis of adrenal glucocorticoids and causes an accumulation of circulating mineralocorticoids. As a consequence of potent CYP17 hydroxylase inhibition (i.e., lack of lyase selectivity), AA must be co-administered with the cortisol replacement prednisone and patients may experience the effects of mineralocorticoid excess syndrome (MES). Herein, we describe rationally-designed, CYP17 lyase-selective inhibitors that could prove safer and more effective than abiraterone. Using proprietary methodology, the high-affinity pyridine or imidazole metal-binding group found in current clinical CYP17 inhibitors was replaced with novel, less avid, metal-binding groups in concert with potency-enhancing molecular scaffold modifications. This process produced a unique series of CYP17 lyase-selective inhibitors that included the oral agent 6 (VT-464), now in Phase 2 prostate cancer clinical trials. The chemical methodology described is potentially applicable to the design of new and more effective metalloenzyme inhibitor treatments for a broad array of diseases.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Derivatives of naphthalene with comt inhibiting activity

Compounds of formula (I′), wherein A, R1 to R3 and t are as defined in the disclosure, exhibit COMT enzyme inhibiting activity so that they are useful as COMT inhibitors.